Brian Schwartz

Brian joined Step Pharma in 2022. He previously served for 12 years at ArQule, where he was CMO and Head of Research and Development; during this time, he led the clinical development of the BTK inhibitor ARQ 531 before the company’s $2.7 billion acquisition by Merck in 2020. His previous roles include CMO and Senior Vice President, Clinical and Regulatory Affairs, at Ziopharm, where he oversaw the development of new cancer drugs. Earlier in his career, he held leadership roles at Bayer Healthcare and Leo Laboratories. Alongside his role at Step Pharma, Brian continues to act as a consultant to other biotech companies, and also serves on the boards of Mereo BioPharma, Enlivex, Cyclacel Pharmaceuticals and Infinity Pharmaceuticals.

Brian, who practised medicine prior to his career in the biopharmaceutical industry, holds a medical degree from the University of Pretoria, South Africa, and completed a fellowship at the University of Toronto, Canada.